Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
AUROBINDO PHARMA | GSK PHARMA | AUROBINDO PHARMA/ GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 18.1 | -83.0 | - | View Chart |
P/BV | x | 3.9 | 12.4 | 31.6% | View Chart |
Dividend Yield | % | 0.3 | 1.3 | 21.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
GSK PHARMA Mar-19 |
AUROBINDO PHARMA/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 3,595 | 23.1% | |
Low | Rs | 527 | 1,253 | 42.1% | |
Sales per share (Unadj.) | Rs | 333.9 | 184.7 | 180.8% | |
Earnings per share (Unadj.) | Rs | 40.4 | 26.3 | 153.5% | |
Cash flow per share (Unadj.) | Rs | 51.8 | 29.2 | 177.5% | |
Dividends per share (Unadj.) | Rs | 2.50 | 20.00 | 12.5% | |
Dividend yield (eoy) | % | 0.4 | 0.8 | 44.7% | |
Book value per share (Unadj.) | Rs | 237.1 | 126.3 | 187.7% | |
Shares outstanding (eoy) | m | 585.91 | 169.40 | 345.9% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 13.1 | 15.5% | |
Avg P/E ratio | x | 16.8 | 92.2 | 18.2% | |
P/CF ratio (eoy) | x | 13.1 | 83.1 | 15.8% | |
Price / Book Value ratio | x | 2.9 | 19.2 | 14.9% | |
Dividend payout | % | 6.2 | 76.1 | 8.1% | |
Avg Mkt Cap | Rs m | 397,569 | 410,626 | 96.8% | |
No. of employees | `000 | 17.9 | 5.0 | 360.0% | |
Total wages/salary | Rs m | 25,849 | 5,372 | 481.2% | |
Avg. sales/employee | Rs Th | 10,956.9 | 6,306.7 | 173.7% | |
Avg. wages/employee | Rs Th | 1,447.7 | 1,083.1 | 133.7% | |
Avg. net profit/employee | Rs Th | 1,324.3 | 898.0 | 147.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 31,281 | 625.4% | |
Other income | Rs m | 1,553 | 1,023 | 151.8% | |
Total revenues | Rs m | 197,189 | 32,304 | 610.4% | |
Gross profit | Rs m | 39,519 | 6,009 | 657.7% | |
Depreciation | Rs m | 6,680 | 486 | 1,374.4% | |
Interest | Rs m | 2,626 | 6 | 43,766.7% | |
Profit before tax | Rs m | 31,767 | 6,540 | 485.7% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 287 | -306.8% | |
Tax | Rs m | 7,269 | 2,373 | 306.3% | |
Profit after tax | Rs m | 23,645 | 4,454 | 530.9% | |
Gross profit margin | % | 20.2 | 19.2 | 105.2% | |
Effective tax rate | % | 22.9 | 36.3 | 63.1% | |
Net profit margin | % | 12.1 | 14.2 | 84.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 20,061 | 765.9% | |
Current liabilities | Rs m | 120,429 | 14,543 | 828.1% | |
Net working cap to sales | % | 17.0 | 17.6 | 96.2% | |
Current ratio | x | 1.3 | 1.4 | 92.5% | |
Inventory Days | Days | 135 | 57 | 238.1% | |
Debtors Days | Days | 64 | 14 | 453.0% | |
Net fixed assets | Rs m | 103,909 | 14,343 | 724.5% | |
Share capital | Rs m | 586 | 1,694 | 34.6% | |
"Free" reserves | Rs m | 138,322 | 19,704 | 702.0% | |
Net worth | Rs m | 138,908 | 21,398 | 649.2% | |
Long term debt | Rs m | 1,800 | 2 | 89,975.0% | |
Total assets | Rs m | 264,544 | 39,113 | 676.4% | |
Interest coverage | x | 13.1 | 1,091.0 | 1.2% | |
Debt to equity ratio | x | 0 | 0 | 13,860.4% | |
Sales to assets ratio | x | 0.7 | 0.8 | 92.5% | |
Return on assets | % | 9.9 | 11.4 | 87.1% | |
Return on equity | % | 17.0 | 20.8 | 81.8% | |
Return on capital | % | 23.8 | 31.9 | 74.7% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 534 | 18,224.0% | |
Fx outflow | Rs m | 40,589 | 7,091 | 572.4% | |
Net fx | Rs m | 56,727 | -6,557 | -865.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 3,994 | 406.1% | |
From Investments | Rs m | -28,768 | -1,433 | 2,007.0% | |
From Financial Activity | Rs m | 19,191 | -3,584 | -535.5% | |
Net Cashflow | Rs m | 6,656 | -1,023 | -650.5% |
Indian Promoters | % | 54.1 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 50.7 | - | |
Indian inst/Mut Fund | % | 8.0 | 10.2 | 77.9% | |
FIIs | % | 27.7 | 23.8 | 116.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 10.2 | 15.4 | 66.2% | |
Shareholders | 69,601 | 102,036 | 68.2% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: ABBOTT INDIA NATCO PHARMA DIVIS LABORATORIES PIRAMAL ENTERPRISES ALKEM LABORATORIES
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More